THERAVANCE BIOPHARMA INC's ticker is and the CUSIP is 88339KAA0. A total of 23 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $4,614,000 | -14.6% | 4,960,000 | -9.8% | 0.10% | -1.0% |
| Q1 2022 | $5,405,000 | +1.7% | 5,500,000 | 0.0% | 0.10% | -5.4% |
| Q4 2021 | $5,313,000 | +2.5% | 5,500,000 | 0.0% | 0.11% | -6.7% |
| Q3 2021 | $5,182,000 | -1.6% | 5,500,000 | 0.0% | 0.12% | +4.4% |
| Q2 2021 | $5,264,000 | -7.3% | 5,500,000 | 0.0% | 0.11% | -21.9% |
| Q1 2021 | $5,680,000 | +8.0% | 5,500,000 | 0.0% | 0.15% | -1.4% |
| Q4 2020 | $5,257,000 | +5.7% | 5,500,000 | 0.0% | 0.15% | -22.1% |
| Q3 2020 | $4,973,000 | -7.7% | 5,500,000 | 0.0% | 0.19% | -21.8% |
| Q2 2020 | $5,385,000 | -2.8% | 5,500,000 | 0.0% | 0.24% | -9.7% |
| Q1 2020 | $5,538,000 | +103.6% | 5,500,000 | +175.0% | 0.27% | +8.0% |
| Q2 2017 | $2,720,000 | -57.6% | 2,000,000 | -60.0% | 0.25% | -61.9% |
| Q1 2017 | $6,412,000 | -38.4% | 5,000,000 | -44.4% | 0.65% | -33.8% |
| Q4 2016 | $10,407,000 | – | 9,000,000 | – | 0.99% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Context Capital Management, LLC | 6,000,000 | $5,827,000 | 3.55% |
| DeepCurrents Investment Group LLC | 21,223,000 | $20,803,000 | 1.80% |
| ZAZOVE ASSOCIATES LLC | 19,230,000 | $18,725,000 | 1.77% |
| Mohican Financial Management, LLC | 500,000 | $494,000 | 1.61% |
| Castle Creek Arbitrage, LLC | 5,149,000 | $5,015,000 | 1.47% |
| LINDEN ADVISORS LP | 62,688,000 | $61,071,000 | 1.40% |
| Verition Fund Management LLC | 10,817,000 | $10,504,000 | 0.41% |
| WOLVERINE ASSET MANAGEMENT LLC | 24,100,000 | $23,451,000 | 0.32% |
| Baupost Group | 30,000,000 | $29,213,000 | 0.24% |
| SSI INVESTMENT MANAGEMENT LLC | 2,763,000 | $2,676,000 | 0.22% |